Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Science Advances|September 28, 2022
Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker-driven learning frameworkSabrina H Rossi, Izzy Newsham, Sara Pita, et al.
Oncogene|January 17, 2025
Evidence of DNA methylation heterogeneity and epipolymorphism in kidney cancer tissue samplesSabrina H Rossi, Victoria Dombrowe, Laura Godfrey, et al.
American Journal of Human Genetics|May 7, 2016
Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome SequencingLixing Yang, Mi-Sook Lee, Hengyu Lu, et al.
Clinical Drug Investigation|July 12, 2025
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid ArthritisGerd Burmester, Jakub Trefler, Artur Racewicz, et al.
Breast Cancer Research : BCR|February 23, 2024
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 casesMinsun Jung, Seung Geun Song, Soo Ick Cho, et al.
Head & Neck|October 13, 2023
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinomaDong Hyun Kim, Yoojoo Lim, Chan-Young Ock, et al.
NPJ Precision Oncology|December 11, 2025
Differential implications of tumor endothelial cell and lymphocyte densities in advanced hepatocellular carcinoma patients treated with immunotherapyGwangil Kim, Beodeul Kang, Jung Yong Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract CancerYeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
Open Forum Infectious Diseases|August 31, 2022
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019Jin Yong Kim, Oana Săndulescu, Liliana-Lucia Preotescu, et al.
Gastroenterology|May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.
Pageof 4